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1. Introduction 2. Experimental 
The widespread interest in developing structure- 
activity correlations for opioid peptides [1-3] has 
led to a large number of investigations on the pre- 
ferred solution conformations of enkephalins [4-11 ]. 
The results of these studies have led to proposals 
ranging from/3-turn conformations. With Gly2-Gly 3 
[14] or Gly3-Phe 4 [4-10] as the corner residues. 
Evidence for the lack of preferred conformations in 
solutions, resulting from dynamic averaging between 
an ensemble of structures, has also been presented 
[ 11 ]. While a consensus has yet to be reached on the 
solution conformations of enkephalins, there is gen- 
eral agreement that receptor interactions presumably 
involve a folded, defined conformation of the penta- 
peptide [12-14]. The recognition of multiple recep- 
tor sites for opioid ligands [ 15-17], has provided a
further impetus for studies of conformational flexibil- 
ity in enkephalins, with the possibility that interac- 
tion at/a and 6 sites may be mediated through differ- 
ent conformations of the peptides [18]. Here, we 
describe an unusual solvent-dependent conforma- 
tional transition, in the protected fragment Boc-Gly- 
Gly-Phe-Met-NH2 and MetS-enkephalinamide which 
is abolished on restricting conformational freedom by 
substitution of Gly by a-aminoisobutyryl (Aib) resi- 
dues [19,20]. 
All peptides were synthesized by solution phase 
procedures using DCC or DCC-l-hydroxybenzotri- 
azole mediated couplings. Peptides were characterized 
by 270 MHz 1H NMR and checked for homogeneity 
by TLC on silica gel. CD spectra were recorded on a 
JASCO J-20 spectropolarimeter using cells of 1 mm 
pathlength. Molar ellipticities [0 ] M were calculated 
using the formula: 
[0]M = (0ob s × Mr)/10 C. l deg. cm 2 . dmo1-1 
where 
0oh s = observed reading in degrees; 
C = concentration i  g/ml; 
l --- pathlength in cm. 
1H NMR studies were carried out on a Bruker 
WH-270 FT-NMR spectrometer at the Bangalore 
NMR Facility. Amide NH resonances of Phe and Met 
were unambiguously identified by spin decoupling 
experiments, which established the connectivities 
between C#H2, Call and NH protons. Variable tem- 
perature measurements were carried out in (CD3)250 
over 20-80°C, at 10 mg peptide/ml. 
3. Results and discussion 
Abbreviations: Aib, a-aminoisobutyryl; DCC, N,N'-dicyclo- 
hexylcarbodiimide; TLC, thin-layer chromatography; Boc, 
t-butyloxycarbonyl; TFE, trifluoroethanol 
* To whom correspondence should be addressed 
Fig.1 shows the CD spectrum of Boc-Gly-Gly- 
Phe-Met-NH2 (l) in methanol, trifluoroethanol 
(TFE) and a 1 : 1 (v/v) mixture of these solvents. In 
MeOH, a weak negative band at 235 nm and a strong 
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Fig,2. CD spectra of Tyr-Gly-Giy-Phe-Met-NH 2 (1.74 mM) 
in: (a) MeOH and (b) TFE; Boc-Tyr-Gly-Gly-Phe-Leu- 
NH~ (1.53 mM) in (c) MeOH and (d) TFE. 
Fig.1. CD spectra of Boc-Gly-Gly-Phe-Met-NH 2 1 
(1.96 mM) in: (a) TFE; (b) MeOH; (c) TFE-MeOH, 1 : 1 (v/v). 
positive band at 218 nm is observed, whereas in TFE 
there is a dramatic hange, with only a negative band 
at 228 nm. This suggests that the peptide undergoes a 
large conformational change on going from MeOH to 
TFE. Interestingly, the spectrum in a 1:1 solvent 
mixture (fig.1 c), exhibits CD bands characteristic of
both solvents, suggesting that different conforma- 
tional states may be populated. A similar solvent 
dependent reversal of the signs of the CD bands is 
also observed in MetS-enkephalinamide (Tyr -Gly-  
Gly-Phe-Met-NH2) and Boc-Tyr-Gly-Gly-Phe- 
Leu-NH2 (fig.2). Aib residues, in which both C a 
hydrogens of Gly are replaced by methyl groups, can 
be used to restrict he conformational flexibility of 
small acyclic peptides [21]. Fig.3 shows the CD spec- 
tra of 3 tetrapeptides, in which the Gly residues are 
separately and simultaneously replaced by Aib resi- 
dues. Both Boc.Aib-Gly-Phe-Met-NH~ (2) and Boc- 
Aib-Aib-Phe-Met-NH2 (3) show positive CD bands 
at 218 nm in MeOH as observed for 1. However, in 
the case of Boc-Gly-Aib-Phe-Met-NHz (4) a nega- 
tive band at 216 nm is observed. In all the Aib-substi- 
tuted peptides there is no change in the sign of the 
CD band on going from MeOH to TFE. Small shifts in 
band position and changes in intensity are observed. 
The relevant CD parameters for these peptides are 
summarized in table 1. The CD spectra were concen- 
tration-dependent over I -2  rnM in TFE. 
The above results establish that Boc-Gly-Gly- 
Phe-Met-NH2 (1), MetS-enkephalinamide and Boc- 
Tyr-Gly-Gly-Phe-Leu-NH2 show pronounced 
solvent-dependent conformational equilibria. Substi- 
tution of Gly by Aib abolishes this degree of flexi- 
bility. Earlier studies of Aib peptides, have clearly 
established the propensity of Aib-X and X-Aib 
sequences to adopt/~-turn conformations, stabilized 
by an intramolecular 4 ~ 1 hydrogen bond [21-25]. 
1H NMR studies of the tetrapeptides have been car- 
ried out to delineate the intramolecularly h drogen- 
bonded NH groups. Temperature coefficients (dS/dT) 
of the Phe and Met NH-groups, determined in
(CD3)~SO, are summarized in table 1. In 2 the Phe 
33 
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Fig.3. CD spectra of protected tetrapeptide amides. Boc- 
Aib-Gly-Phe-Met-NH 2 2 in (a) MeOH and (b) TFE; Boc- 
Aib-Aib-Phe-Met-NH: 3 in (c) MeOH and (d) TFE; Boc- 
Gly-Aib--Phe-Met-NH 2 4 in (e) MeOH and (f) TFE. 
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NH has a tow d6/dTvalue (2.77 × t0 -3 ppm/°C) 
characteristic of a solvent shielded or intramolecu- 
larly hydrogen-bonded NH group, whereas the d6/dT 
value for the Met NH is indicative of a solvent- 
exposed proton [26]. The df/dT values in table 1 also 
suggest that in 3 and 4 both Phe and Met NH groups 
are intramolecularly h drogen bonded. These results, 
together with the known stereochemical preferences 
of Aib residues [21-25] lead us to conclude that in 
2,/3-turn structures having Aib-Gly as the corner esi- 
dues are significantly populated. This conformation is 
stabilized by a 4 ~ 1 hydrogen bond between the Boc 
CO- and Phe NH-groups (fig.4a). In peptides 3 and 4 
the NMR data favours incipient 3lo helical structures 
formed by consecutive type III ~3-turns having X-A ib  
and Aib-Phe as the corner esidues (X = Aib in 3 and 
Gly in 4). These conformations require that both Phe 
and Met NH groups are intramotecularly h drogen- 
bonded (fig,4b). Such structures have been unambig- 
Table 1 
CD parameters and NMR temperature coefficients (NH protons) in enkephalin fragments 
Peptide Solvent (mM) ?'max [0]M × 10 -3 d6/dT X 103 
(rim) (deg, cm 2 . drool -1) (ppm/°C) 
Boc-Gly-Gly-Phe- MeOH (1.96) 218 +10.6 
Met-NH2 1 TFE (1.96) 227.5 -5.2 Phe 5.55 a 
MeOH + (1.96) 218 +2.9 Met 5.55 
TFE 231 -3.5 
Boc-Aib-Gly-Phe- MeOH (1.86) 218 +7.84 Phe 2.77 
Met-NH2 2 TFE (1.86) 218 +5.42 Met 3.70 
Boc-Aib-Aib-Phe- MeOH (1.77) 221 +3.5 Phe 2.31 
Met-NH= 3 TFE (1.77) 218 +4.52 Met 1.85 
Boc-Gly-Aib-Phe- MeOH (1.86) 216 -7.25 Phe 1.85 
Met-NH 2 4 TFE (1.86) 212 -8.96 Met 2.32 
Tyr-Gly-Gly-Phe- MeOH (1.74) 225 -2.9 Phe 3.70 
Met-NH 2 TFE (1,74) 230 +2.4 Met 4.63 
Boc-Tyr-Gly-Gly- MeOH (1.53) 225 +5.3 - 
Phe-Leu-NH 2 TFE (1.53) 232 -4.8 
a Temperature coefficients determined for Boc-Gly-Gly-Phe-Met-OMe 
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Fig.4. Proposed conformations for (a) Boc-Aib-Gly-Phe-Met-NH2 2 and (b) Boc-Aib-Aib-Phe-Met-NH 2 3or Boc-Gly-Aib- 
Phe-Met-NH~ 4. 
uously established in solution and solid state for Aib 
containing oligopeptides [21-25].  
The CD data presented above show that peptides 
with the Gly-Gly sequence xhibit similarities to the 
Aib analogs 2 or 4, depending on the solvent condi- 
tions. It thus appears that both Gly2-Gly a and Gly 3- 
Phe 4 ~-turn conformations for enkephalins may be 
energetically close, leading to large solvent-dependent 
changes in conformer populations. This may account 
for the apparently conflicting proposals put forward 
in the literature. Theoretical studies have favoured 
Gly2-Gly 3/3-turn structures [14,27] and a type I' 
Gly2-Gly 3/3-turn has been observed in the solid state 
[28]. Spectroscopic studies in solution have, however, 
been interpreted in terms of Glya-Phe 4/3-turns [10] 
or random conformations [11 ]. The reversal in signs 
of the CD bands in Tyr -G ly -Gly-Phe-Met-NH2 as 
compared to 1 may reflect the influence of the Tyr 
residue on the energetics of the different fl-turn struc- 
tures. The studies on the model tetrapeptides reported 
here eliminate contributions due to the aromatic ring 
of Tyr, a feature considered in earlier studies of 
enkephalins [ 18]. Detailed interpretations of enke- 
phalin CD spectra must also consider the changes in 
the signs of the bands for the various categories of 
/3-turns, predicted from theoretical calculations [29]. 
The possibility that different well-defined, folded 
conformational states are populated in peptides with 
sequences related to enkephalins, is relevant in view 
of recent reports of multiple receptor sites for opioid 
ligands [ 15,17]. Biological responses induced by 
opioid peptides could, in principle, be modulated by 
altering populations of folded conformations. 
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